Alpha Cancer is developing disruptive immunotherapy and immuno-oncology products.

ACT-101 is a high value immune modulator for treating multiple sclerosis, myasthenia gravis and IBD. ACT-903 is the first true immune-oncology product safety targeting over 80% of solid and liquid tumors while simultaneously killing myeloid derived suppressor cells which then unlocks the patient’s immune to address the cancer as well.

Alpha Cancer Logo



Event details

Date: June 8 - 12, 2020

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


34 in total